Drug Profile


Alternative Names: BAY-2306001; FXI ASO; IONIS-FXIRX; ISIS 404071; ISIS-416858; ISIS-FXIRX

Latest Information Update: 11 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Isis Pharmaceuticals
  • Developer Bayer; Ionis Pharmaceuticals
  • Class Anticoagulants; Antisense oligonucleotides; Antithrombotics
  • Mechanism of Action Factor XI inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Thrombosis; Venous thromboembolism

Most Recent Events

  • 11 Dec 2017 Ionis Pharmaceuticals plans to initiate a phase II pharmacokinetics and pharmacodynamics trial in Austria, Belgium, Bulgaria, Canada, Czech Republic, Netherlands, Spain (SC) (NCT03358030) (EudraCT2017-002165-21)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Thrombosis(Prevention, In volunteers) in USA (SC, Injection)
  • 13 Nov 2016 Adverse events and efficacy data from a phase II trial in Thrombosis (Prevention) released by Ionis Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top